Synthes Awarded Permanent Injunction and US$ 21 MM in Enhanced Damages, Interest and Costs in ProDisc Patent Case against Medtronic
West Chester (PA), USA, September 7, 2009
Synthes (SWX: SYST.VX) reported today about recent favorable Court rulings in its ProDisc patent litigation against Medtronic.
On August 26, 2009, the U.S. District Court in Memphis, TN, (the "Court") permanently enjoined Medtronic from infringing Synthes' U.S. Patent No. 6,936,071, covering Synthes' ProDisc-L artificial disc replacement device. The Court also doubled Synthes' actual damages (for the period until the end of 2008), with the total award now exceeding US$ 21.0 million in damages, interest and costs. In addition, the Court ruled that Synthes is entitled to an award of its attorneys' fees because of Medtronic's willful infringement.
"We are pleased that the Court has upheld the jury's verdict," said Michel Orsinger, President and CEO of Synthes. "Synthes has made substantial investments towards the ProDisc artificial disc replacement devices, and the rulings by the Court confirm our intellectual property rights in that technology," he continued.
In 2007, Synthes filed suit against Medtronic, asserting that their Maverick products infringe the '071 patent. In November 2008, a jury had reached a verdict that Medtronic willfully infringed the '071 patent by its manufacture and sale of the Maverick product lines. On August 19, 2009, the Court denied Medtronic's motion for a new trial. Medtronic is appealing these rulings to the U.S. Court of Appeals.
ProDisc-L is a total disc replacement device used to replace diseased vertebral discs in the lumbar spine. It was approved in 2006 by the FDA (Food and Drug Administration) for commercial sale in the U.S. and has since shown good clinical results.
Synthes: A leading medical device company
Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.
For further information please contact
Gilgian Eisner, Investor Relations Synthes, Inc.
Phone +41 32 720 47 45
Restrictions Subject to US Securities Law
Synthes, Inc. management believes certain statements in this media release may constitute "Forward-Looking Statements" within the meaning of the "Private Securities Litigation Reform Act of 1995". These statements include but are not limited to those with respect to the potential for Synthes to offer new products and market existing ones, as well as the expected sales and sales growth of Synthes. These statements are made on the basis of management's views and assumptions regarding future events and business performance as of the time the statements are made. Actual results may differ materially from those expressed or implied. Such differences may result from the ability of Synthes to successfully develop and introduce new products and services and market existing products and services in a competitive marketplace and changes in the economic conditions that may affect the performance of the operations of Synthes. In addition, changes in competitive conditions and regulatory developments may affect future business performance, and changing market conditions may affect the valuation of Synthes securities.
In addition, it should be noted that past financial and operational performance of the company is not necessarily indicative of future financial and operational performance. Synthes undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
The securities of Synthes have been offered and sold outside the United States and have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"). Such securities may not be offered, sold or transferred in the U.S. or to U.S. Persons (as defined in the regulations of the Securities Act), except pursuant to a registration statement filed under the Securities Act or under an applicable exemption under the Securities Act. Hedging transactions involving such securities may not be conducted unless in compliance with the Securities Act. The Synthes securities are deemed "Restricted Securities" as that term is defined in Rule 144 under the Securities Act.